Evaluation of semi-quantitative method for quantification of dopamine transporter in human PET study with 18F-FE-PE2I

详细信息    查看全文

• 作者：Yoko Ikoma ; Takeshi Sasaki ; Yasuyuki Kimura ; Chie Seki…
• 关键词：Positron emission tomography ; 18F ; FE ; PE2I ; Binding potential ; Standardized uptake value ratio (SUVR) ; Occupancy
• 刊名：Annals of Nuclear Medicine
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：29
• 期：8
• 页码：697-708
• 全文大小：689 KB
• 参考文献：1.Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand [18F]尾-CFT in assessing disability in Parkinson鈥檚 disease. J Neurol Neurosurg Psychiatry. 1999;67(6):737鈥?1.PubMed Central CrossRef PubMed
  2.Ginovart N, Lundin A, Farde L, Halldin C, B盲ckman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington鈥檚 disease. Brain. 1997;120(3):503鈥?4.CrossRef PubMed
  3.Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57(3):229鈥?8.CrossRef PubMed
  4.Arakawa R, Ichimiya T, Ito H, Takano A, Okumura M, Takahashi H, et al. Increase in thalamic binding of [11C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res. 2009;43(15):1219鈥?3.CrossRef PubMed
  5.Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, et al. [11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging. 2003;30(9):1220鈥?0.CrossRef PubMed
  6.Varrone A, Steiger C, Schou M, Takano A, Finnema SJ, Guilloteau D, et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. 2009;63(10):871鈥?0.CrossRef PubMed
  7.Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging. 2006;33(6):657鈥?8.CrossRef PubMed
  8.Hirvonen J, Johansson J, Ter盲s M, Oikonen V, Lumme V, Virsu P, et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab. 2008;28(5):1059鈥?9.CrossRef PubMed
  9.DeLorenzo C. Kumar JSD., Zanderigo F, Mann JJ, Parsey RV. Modeling considerations for in vivo quantification of the dopamine transporter using [11C]PE2I and positron emission tomography. J Cereb Blood Flow Metab. 2009;29(7):1332鈥?5.PubMed Central CrossRef PubMed
  10.Seki C, Ito H, Ichimiya T, Arakawa R, Ikoma Y, Shidahara M, et al. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models. Ann Nucl Med. 2010;24(4):249鈥?0.CrossRef PubMed
  11.Shetty HU, Zoghbi SS, Liow JS, Ichise M, Hong J, Musachio JL, et al. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I. Eur J Nucl Med Mol Imaging. 2007;34(5):667鈥?8.
  12.Varrone A, T贸th M, Steiger C, Takano A, Guilloteau D, Ichise M, et al. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. J Nucl Med. 2011;52(1):132鈥?.CrossRef PubMed
  13.Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, et al. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. J Nucl Med. 2012;53(7):1065鈥?3.CrossRef PubMed
  14.Ito H, Hietala J, Blomqvist G, Halldin C, Farde L. Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab. 1998;18(9):941鈥?0.CrossRef PubMed
  15.Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroImage. 1996;4(3 Pt 1):153鈥?.CrossRef PubMed
  16.Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45(1):71鈥?.CrossRef PubMed
  17.Logan J, Fowler JS, Volkow ND, Ding YS, Wang GJ, Alexoff DL. A strategy for removing the bias in the graphical analysis method. J Cereb Blood Flow Metab. 2001;21(3):307鈥?0.CrossRef PubMed
  18.Schou M, Steiger C, Varrone A, Guilloteau D, Halldin C. Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. Bioorg Med Chem Lett. 2009;19(16):4843鈥?.CrossRef PubMed
  19.Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Bioi Psychiatry. 1993;33(4):227鈥?5.CrossRef
  20.Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology. 1993;110(3):265鈥?2.CrossRef PubMed
  21.Nakashima Y, Farde L. Comparison of currently applied methods for PET quantification of specific [11C]raclopride binding. J Cereb Blood Flow Metab. 1995;15:S643.
  22.Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, et al. Striatal D2 receptor status in patients with Parkinson鈥檚 disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 1992;31(2):184鈥?2.CrossRef PubMed
  23.Rinne JO, Laihinen A, Rinne UK, Nagren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson鈥檚 disease. Mov Disord. 1993;8(2):134鈥?.CrossRef PubMed
  24.Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med. 1993;34(4):609鈥?3.PubMed
  25.Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab. 1996;16(1):42鈥?2.CrossRef PubMed
  26.Farde L, Eriksson L, Blomquist G, Halldin C. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET鈥揳 comparison to the equilibrium analysis. J Cereb Blood Flow Metab. 1989;9(5):696鈥?08.CrossRef PubMed
  
• 作者单位：Yoko Ikoma (1)
  Takeshi Sasaki (1)
  Yasuyuki Kimura (1)
  Chie Seki (1)
  Yoshiro Okubo (2)
  Tetsuya Suhara (1)
  Hiroshi Ito (1) (3)
  
  1. Molecular Imaging Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan
  2. Department of Neuropsychiatry, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan
  3. Advanced Clinical Research Center, Fukushima Medical University, 1 Hikariga-oka, Fukushima, 960-1295, Japan
  
• 刊物主题：Nuclear Medicine; Imaging / Radiology;
• 出版者：Springer Japan
• ISSN：1864-6433

文摘

Objectives Positron emission tomography (PET) with 18F-FE-PE2I is useful for investigating the function of dopamine transporter, and kinetics of 18F-FE-PE2I could be described by standard two-tissue compartment model (2CM) using plasma input function. In this study, we investigated the feasibility of semi-quantitative methods for estimating binding potential (BP_ND) and transporter occupancy to shorten the scan period and to reduce the effect of statistical noise on quantitative outcomes using computer simulation and human PET studies with 18F-FE-PE2I.